Q: What is the primary advantage of using the pIII vs. pVIII display site?

A: The choice is driven by the insert size and the desired selection stringency. pIII is used for larger inserts (e.g., antibody fragments, protein domains) and is critical for high-affinity selection due to its monovalent display capability, which minimizes avidity effects. pVIII is used for short peptides and provides high-copy-number display, which is beneficial for identifying ligands with moderate affinity or for applications requiring a strong signal (e.g., screening for epitopes).

Q: How does Creative Biolabs ensure the infectivity of phages displaying large proteins?

A: We utilize a phagemid system in conjunction with a helper phage. The library sequence is cloned into the phagemid, which expresses the fusion protein (e.g., pIII-scFv). The helper phage simultaneously supplies the wild-type coat proteins (in trans). This ensures that a sufficient amount of wild-type pIII is incorporated into the virion, guaranteeing phage infectivity while still allowing the display of the recombinant protein, resulting in the desired monovalent presentation.

Q: What is the minimum diversity required for a successful antibody fragment library screen?

A: While the theoretical diversity can reach 10^14 in nature, practical phage display libraries typically range from 10^9 to 10^11 independent clones. Creative Biolabs aims for and routinely achieves a functional diversity of 10^10 to 10^11 clones. This high level of diversity is essential to ensure that the library covers a vast sequence space and statistically contains binders capable of recognizing the target antigen.

Q: Can M13 display be used to screen against non-protein targets, such as small molecules or carbohydrates?

A: Absolutely. Phage display is not limited to protein-protein interactions. By immobilizing the non-protein target (e.g., a chemically synthesized small molecule conjugated to a carrier or a carbohydrate) onto a solid phase, our biopanning protocols can effectively screen large peptide or antibody libraries to identify binders specific to these complex targets.

M13 Display System Introduction

M13 Phage Display Sites Our Platform Our Services FAQs

M13 Phage: The Ideal Molecular Scaffold

Fig 1. Structure of M13 phage. (Creative Biolabs Original)

Phage display technology has emerged as a transformative solution, offering a powerful method to link a phenotype (the displayed peptide or protein) to its genotype (the corresponding DNA sequence) through the utilization of bacteriophages as versatile molecular display vehicles. Among the various phage systems, the M13 filamentous phage system is overwhelmingly preferred for its stability, ease of manipulation, and unparalleled capacity for large-scale library screening. The M13 bacteriophage is a non-lytic, single-stranded DNA virus that exclusively infects Escherichia coli strains carrying the F-pilus. Its distinct morphology as a filamentous particle, measuring approximately 6 nm in diameter and 880 nm in length, is structurally defined by its well-characterized, circular, single-stranded genome encapsulated by five primary structural proteins: pIII, pVI, pVII, pVIII, and pIX.

Creative Biolabs is at the forefront of this field, offering comprehensive development and screening services centered on the M13 display system, enabling the isolation of high-affinity peptides, proteins, and antibody fragments from libraries comprising millions of distinct molecular entities. This foundational technology drastically shortens the development cycle for novel binders and reduces production costs by eliminating the need for conventional animal immunization protocols.

Leverage Our End-to-End M13 Display Solutions to Rapidly Advance Your Research Pipeline

M13 Phage Display Sites and Their Strategic Utilization

Effective phage display hinges on the ability to fuse the heterologous (exogenous) sequence (the peptide, scFv, or Fab) to a phage coat protein without compromising the phage's assembly, stability, or infectivity. The M13 system offers two primary coat proteins, pIII and pVIII, each providing unique strategic advantages based on the size of the insert and the desired display valency.

Display on the Minor Coat Protein (pIII)

Display on the Major Coat Protein (pVIII)

The pIII protein, essential for phage infection of E. coli, serves as the most common display site for large peptides and complex protein domains, including antibody fragments.

Structure and Functionality: pIII is located at the tail end and is crucial for initiating infection. It is segmented into three functional domains—N1, N2, and CT—connected by glycine-rich linkers (G1, G2). The N2 domain is the receptor-binding region (binding to the F-pilin), while N1 interacts with the TolA protein for phage invasion. The CT domain is involved in phage assembly.
Insertion Sites and Considerations: The pIII protein accommodates larger inserts. However, direct fusion to the CT domain can lead to a loss of phage infectivity. To circumvent this, the use of a "helper phage" is standard practice. The helper phage provides wild-type pIII in trans alongside the recombinant fusion protein, enabling the production of "monovalent" display phages.
Monovalent Display Advantage: Monovalent display—where the average phage exhibits less than one fusion protein copy—is achieved through auxotrophic superinfection and differential protein expression. This low valency is critical for selecting high-affinity binders, as it prevents the avidity effect from masking true low-affinity interactions, mimicking the required stringency of a single molecular interaction.

Start Your M13 Display Project Today

Creative Biolabs' M13 Phage Display Platform

Creative Biolabs leverages its deep knowledge and extensive experience to operate a state-of-the-art Phage Display Platform that overcomes the common technical hurdles associated with library construction and screening. Our expertise in manipulating the M13 system ensures that clients benefit from stable, high-titer, and biologically robust phage libraries.

We have refined the genetic engineering techniques necessary for precise control over valency (monovalent or multivalent display), offering unparalleled flexibility in screening strategies tailored to the target antigen's characteristics and the required binder affinity. Our proprietary methods for managing helper phage infection and expression ratios maximize the diversity and quality of the output, directly translating into a higher success rate for identifying lead candidates.

Request a Consultation with Our M13 Specialists

M13 Phage Display based Binder Discovery Services

Fig.3 Fig.1 http://47.109.42.40:8006/images/15ed6b23f638a79eadfaef9dc0dbf527.jpg. (Creative Biolabs Authorized)

Creative Biolabs offers an end-to-end suite of services built upon the highly efficient M13 Phage Display Platform. Our services are designed to address the entire discovery pipeline, from initial library creation to the isolation of functionally validated binders.

M13 Phage Display Library Construction Service

We specialize in constructing high-diversity, functional libraries (up to 10¹¹ independent clones), including naïve, synthetic, and immune libraries, ensuring comprehensive coverage of sequence space for optimal target binding.

Phage Display Library Screening Service (Biopanning)

Utilizing tailored screening protocols, we perform rigorous biopanning against various targets (proteins, cells, tissues, small molecules) to enrich for high-affinity clones, employing sophisticated techniques for counter-selection and elution to maximize specificity.

Phage Display-based Monoclonal Antibody Discovery Service

This is a core strength of our platform, enabling the rapid isolation of fully human or humanized antibody fragments (scFv, Fab) against almost all antigens, circumventing the need for in vivo immunization and offering a faster route to therapeutic development.

FAQs

Q: What is the primary advantage of using the pIII vs. pVIII display site?
A: The choice is driven by the insert size and the desired selection stringency. pIII is used for larger inserts (e.g., antibody fragments, protein domains) and is critical for high-affinity selection due to its monovalent display capability, which minimizes avidity effects. pVIII is used for short peptides and provides high-copy-number display, which is beneficial for identifying ligands with moderate affinity or for applications requiring a strong signal (e.g., screening for epitopes).
Q: How does Creative Biolabs ensure the infectivity of phages displaying large proteins?
A: We utilize a phagemid system in conjunction with a helper phage. The library sequence is cloned into the phagemid, which expresses the fusion protein (e.g., pIII-scFv). The helper phage simultaneously supplies the wild-type coat proteins (in trans). This ensures that a sufficient amount of wild-type pIII is incorporated into the virion, guaranteeing phage infectivity while still allowing the display of the recombinant protein, resulting in the desired monovalent presentation.
Q: What is the minimum diversity required for a successful antibody fragment library screen?
A: While the theoretical diversity can reach 10¹⁴ in nature, practical phage display libraries typically range from 10⁹ to 10¹¹ independent clones. Creative Biolabs aims for and routinely achieves a functional diversity of 10¹⁰ to 10¹¹ clones. This high level of diversity is essential to ensure that the library covers a vast sequence space and statistically contains binders capable of recognizing the target antigen.
Q: Can M13 display be used to screen against non-protein targets, such as small molecules or carbohydrates?
A: Absolutely. Phage display is not limited to protein-protein interactions. By immobilizing the non-protein target (e.g., a chemically synthesized small molecule conjugated to a carrier or a carbohydrate) onto a solid phase, our biopanning protocols can effectively screen large peptide or antibody libraries to identify binders specific to these complex targets.

Discuss Your Screening Needs with Our Experts

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email:

M13 Display System Introduction

M13 Phage: The Ideal Molecular Scaffold

M13 Phage Display Sites and Their Strategic Utilization

Creative Biolabs' M13 Phage Display Platform

M13 Phage Display based Binder Discovery Services

M13 Phage Display Library Construction Service

Phage Display Library Screening Service (Biopanning)

Phage Display-based Monoclonal Antibody Discovery Service

Phage Display-based Peptide Discovery Service

Phage Display-based Stable Binder Discovery Service

Phage Display-based pH-Sensitive Binder Discovery Service

Phage Display-based Internalizing Antibody Discovery

FAQs